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Distinct Dendritic Cell Populations Sequentially
Present Antigen to CD4 T Cells and Stimulate
Different Aspects of Cell-Mediated Immunity
were found interacting at a higher than basal level with
DCs in the lymph nodes after introduction of antigen
(Ingulli et al., 1997, 2002; Dittel et al., 1999; Norbury et
al., 2002; Stoll et al., 2002).
Recently, it has become possible to directly detect
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antibodies. Using this approach, Inaba and SteinmanCenter for Immunology
showed that DCs in the lymph nodes produce pep-University of Minnesota Medical School
tide:MHC II complexes from engulfed cells (Inaba et al.,Minneapolis, Minnesota 55455
1998). Similarly, Reis e Sousa and colleagues showed3 Department of Immunology
that B cells and DCs in the spleen or lymph nodes pro-Howard Hughes Medical Institute
duce peptide:MHC II complexes quickly from intrave-University of Washington
nously (Reis e Sousa and Germain, 1999) or subcutane-Seattle, Washington 98195
ously (Manickasingham and Reis e Sousa, 2000) injected
antigens, respectively. Although these were the first
studies to directly identify defined peptide:MHC II com-Summary
plexes on DCs in vivo, technical limitations prevented
demonstration that these DCs presented the pep-Peptide:MHC II complexes derived from a fluorescent
tide:MHC II complexes to T cells expressing comple-antigen were detected in vivo to identify the cells that
mentary TCRs. Therefore, the identity of the cells thatpresent subcutaneously injected antigen to CD4 T
first present peptide:MHC II complexes and initiate thecells. Skin-derived dendritic cells (DCs) that acquired
activation of naive CD4 T cells in vivo is unknown.the antigen while in the draining lymph nodes were
Although anatomic constraints dictate that intrave-the first cells to display peptide:MHC II complexes.
nous antigens are taken up and presented by DCs inPresentation by these cells induced CD69, IL-2 pro-
the spleen, it is less clear where in the body DCs acquireduction, and maximal proliferation by the T cells. Later,
antigens that are deposited in subcutaneous tissue. An-DCs displaying peptide:MHC II complexes migrated
tigens are carried from tissues by lymphatic vessels intofrom the injection site via a G protein-dependent
the subcapsular sinus of the draining lymph node andmechanism. Presentation by these migrants sustained
through a conduit network that connects to a spaceexpression of the IL-2 receptor and promoted delayed
surrounding the high endothelial venules (Picker and
type hypersensitivity. Therefore, presentation of pep-
Siegelman, 1993; Ebnet et al., 1996; Palframan et al.,
tide:MHC II complexes derived from a subcutaneous 2001). Thus, it is possible that the peptide:MHC II com-
antigen occurs in two temporally distinct waves with plex-displaying DCs identified in the lymph nodes in the
different functional consequences. aforementioned studies (Inaba et al., 1998; Manickasin-
gham and Reis e Sousa, 2000) acquired the antigen at
Introduction the injection site and rapidly migrated into the lymph
nodes. The fact that endotoxin, which is known to stimu-
Although antigen acquisition, processing, and pep- late DC migration (Roake et al., 1995), enhanced the
tide:MHC II presentation to naive CD4 T cells has been number of peptide:MHC II complex-displaying DCs in
studied extensively in vitro, much less is known about the lymph node (Manickasingham and Reis e Sousa,
how these processes occur in vivo during an actual 2000) is consistent with this possibility. However, it is
immune response. Because naive CD4 T cells reside also possible that the DCs that eventually produced
only in the T cell areas of secondary lymphoid organs peptide:MHC II complexes from subcutaneously in-
(lymph nodes, spleen, and mucosal lymphoid tissues) jected antigen were in the lymph nodes at the time of
injection and acquired lymph-borne antigen from the(Jenkins et al., 2001), it follows that initial recognition of
conduits. In support of this possibility, fluorochrome-peptide:MHC II complexes must occur in this location.
labeled antigen was found associated with DCs as earlySince dendritic cells (DCs) are both the predominant
as 4 hr after subcutaneous injection (ManickasinghamMHC II-expressing cells in the T cell areas as well as
and Reis e Sousa, 2000). Against this possibility arethe most potent activators of naive T cells in vitro, it is
tracer studies showing that very little of the proteincurrently thought that DCs are the first cells to present
within the conduits leaks out into the T cell area (Gretzpeptide:MHC II complexes derived from foreign anti-
et al., 2000; Ingulli et al., 2002). To date it has not beengens to naive CD4 T cells in vivo (Steinman et al., 1997;
possible to definitively assess the relative antigen pre-Banchereau and Steinman, 1998). This notion is sup-
sentation contributions of lymph node-resident DCs andported by studies in which naive antigen-specific T cells
DCs that migrate from the tissue where antigen first
enters the body.
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complex derived from this protein, and naive CD4 T cells5 Present address: Department of Medicine, Division of Infectious
Diseases, University of California, San Francisco, California 94143. expressing a TCR specific for the peptide:MHC II com-
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plex could all be monitored simultaneously in the lymph Peptide:MHC II Complexes Are Formed Rapidly and
Maintained for Days in the Lymph Nodenodes. Using this system, we show that two of the five
The tempo of ERFP entry and pE:I-Ab complex forma-potential DC subtypes acquire subcutaneously injected
tion in the draining lymph nodes was characterized byantigen from the lymph and are the first to present pep-
immunohistology and flow cytometry. Thirty minutestide:MHC II complexes to naive CD4 T cells. This presen-
after injection of 50 g of ERFP, a large amount of redtation stimulates IL-2 production and clonal expansion
fluorescence was detected in the subcapsular sinus,of the T cells. Later, dermal DCs migrate into the lymph
and the underlying area between the B cell-rich folliclesnode from the injection site and present peptide:MHC
(Figure 2A). Higher magnification revealed that most ofII complexes to the activated CD4 T cells, maintaining
the ERFP was not associated with cells and was inexpression of the IL-2 receptor and facilitating the pro-
conduits (Gretz et al., 2000). However, flow cytometricduction of effector T cells capable of participating in the
analyses showed that approximately 11% of the cellsdelayed-type hypersensitivity reaction.
in the lymph nodes cells acquired ERFP (Figure 2B),
most of which were CD11c (Figure 2B), CD11b (data
not shown) myeloid cells. The majority of CD11c DCsResults
(Figure 2B) contained ERFP, whereas less than 5% of
B cells had acquired the antigen (data not shown). EvenAntigen Dose-Dependent Detection of Peptide-MHC
at this very early time, some of the DCs in the T cellII Complexes and T Cell Activation
area displayed low levels of pE:I-Ab complexes (Fig-A system was designed in which a protein antigen and
ure 2A).a peptide:MHC II complex derived from this antigen
From 4 to 14 hr after injection, the fraction of totalcould be monitored simultaneously in vivo. The antigen
cells in the lymph nodes that contained ERFP de-was a recombinant 32 kilodalton protein (ERFP) con-
creased from 8% to 4%, although the majority of DCssisting of amino acids 46–74 of the I-Ed MHC II subunit
still contained ERFP over this interval (Figure 2B). DCsat the N terminus and red fluorescent protein DsRed
now displayed much higher levels of pE:I-Ab complexes(Matz et al., 1999) at the C terminus. The inherent red
than at 30 min (Figure 2C) and accounted for almost allfluorescence of this protein was used to detect its pres-
of the cells that displayed pE:I-Ab complexes, althoughence after injection. The I-E sequence was included in
a small number of B cells displaying pE:I-Ab complexesthe protein to take advantage of the Y-Ae monoclonal
were detected in the B cell-rich follicles (Figure 2A)
antibody, which is specific for a complex composed
throughout this period. The cells containing ERFP at
of I-E peptide 52–68 (pE) bound to the I-Ab MHC II
these times could not be detected by microscopy proba-
molecule (Rudensky et al., 1991; Murphy et al., 1992).
bly because this method lacks the sensitivity of flow
Thus, cells that express I-Ab MHC II molecules and take cytometry (Figure 2A). These results demonstrated that
up the ERFP protein should produce pE:I-Ab com- DCs were the only cells that produced pE:I-Ab com-
plexes via antigen processing and become recognizable plexes in the areas occupied by naive CD4 T cells at
by the Y-Ae antibody. early times after ERFP injection.
This system was used to track in vivo antigen pro- Because very little ERFP was detectable in the lymph
cessing and presentation following subcutaneous injec- nodes by microscopy between 4 and 14 hr, it was strik-
tion of ERFP into C57BL/6 mice, which express I-Ab ing to find that cells containing large amounts of ERFP
but not I-E molecules, and thus do not constitutively and displaying high levels of pE:I-Ab complexes ap-
display pE:I-Ab complexes (Murphy et al., 1992). The peared in the T cell areas and subcapsular sinuses 24
subcutaneous injection route was chosen because it is hr after ERFP injection (Figures 2A). Flow cytometric
often used for the delivery of subunit vaccines in humans analysis revealed that these cells were DCs and macro-
(Muderspach et al., 2000). phages (Figure 2C and data not shown). Based on the
Different amounts of ERFP were injected subcutane- known locations of these cells, it is likely that the DCs
ously into the ear to characterize the dose-response occupied the T cell-rich areas and the macrophages
characteristics of pE:I-Ab complex formation. As ex- occupied the subcapsular sinuses. Both populations of
pected (Murphy et al., 1992), E:I-Ab complexes were cells continued to express pE:I-Ab complexes for at
not detected in the draining lymph nodes from mice that least 48 hr although they gradually lost both red fluores-
did not receive ERFP (Figure 1A). In contrast, pE:I-Ab cence and expression of pE:I-Ab complexes over the
complexes were detected by immunohistology at all next several days (data not shown).
ERFP doses tested (8, 16, and 50 g), and the amount
detected increased at each ERFP dose (Figures 1B– Distinct Populations of Tissue-Derived Dendritic Cells
1D). The induction of CD69 on pE:I-Ab-specific TEa Display Peptide:MHC Complexes In Vivo
T cells in adoptive recipients followed a similar dose- Although the preceding results demonstrated that
response curve. CD69 induction above the basal level pE:I-Ab complexes in the T cell areas were displayed
was not detected on TEa T cells in mice injected with primarily by DCs, it was unclear which DC subsets were
0.4 g but increased progressively following injection involved. Recent studies have shown that at least five
of 2, 10, and 50 g of ERFP. Thus, the ERFP doses different CD11c subsets of DCs can be identified in
of 8 and 50 g that were used in subsequent experi- the skin-draining lymph nodes based on expression of
ments were in the linear range for the formation of MHC II, CD8, CD11b, B220, and CD205 (DEC205).
pE:I-Ab complexes and activation of pE:I-Ab-specific Three of these populations, known as myeloid (MHC IIlow,
CD11c, CD11b, CD205, CD8, B220), lymphoidTEa cells.
In Vivo Visualization of Antigen Presentation
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Figure 1. Effect of Antigen Dose on Detec-
tion of pEa:I-Ab Complexes and T Cell Acti-
vation
(A–D) Cervical lymph node sections taken
from C57BL/6 mice at 4 hr after subcutane-
ous ERFP injection of 0 (A), 8 (B), 16 (C),
or 50 g (D) in the ear were processed and
stained with Y-Ae and anti-B220 antibodies
and analyzed by confocal microscopy. T cell
areas are marked with a T.
(E) CD69 expression by TEa T cells trans-
ferred into C57BL/6 mice at 6 or 24 hr after
injection of 0.4, 2, 10, or 50 g of ERFP.
(MHC IIlow, CD11c, CD11b, CD205, CD8, B220) and plasmacytoid DCs, were excluded because very
few of these cells produced pE:I-Ab complexes after(Vremec and Shortman, 1997), and plasmacytoid (MHC
IIlow, CD11c, CD11b, CD205, B220) (Nakano et al., ERFP injection (data not shown). The remaining B220
cells consisted primarily of the other CD11c DC sub-2001; Asselin-Paturel et al., 2001) DCs, are also present
in the spleen and are probably derived from precursors sets (Figures 3J and 3K), which could be divided into
tissue-derived MHC IIhigh and blood-derived MHC IIlowthat enter the lymph nodes from the blood (Ardavin et
al., 2001). All lymph nodes contain a fourth population populations, respectively (Vremec and Shortman, 1997;
Salomon et al., 1998; Ruedl et al., 2000; Henri et al.,of MHC IIhigh, CD11c, CD8low, CD11b, CD205intermediate
interstitial DCs (Anjuere et al., 1999; Ruedl et al., 2000; 2001). Very few CD11c CD8 memory T cells (Huleatt
and Lefrancois, 1995) contaminated the selected popu-Henri et al., 2001; Kamath et al. 2002), and skin-draining
lymph nodes contain a fifth population of MHC IIhigh, lation as evidenced by the absence of CD3 cells (Fig-
ures 3R and 3S).CD11c, CD8intermediate, CD11b, CD205high epidermal
Langerhans cells (Anjuere et al., 1999; Ruedl et al., 2000; This gating strategy was then used to assess the
amounts of ERFP protein and pE:I-Ab complexes onHenri et al., 2001; Kamath et al. 2002). In the case of
skin, the interstitial DCs are derived from the dermis. DC subsets after ERFP injection. As expected, red cells
or pE:I-Ab complexes were not detected on DCs fromBoth Langerhans cells and dermal DCs continually mi-
grate from the skin at a low rate, which is increased control mice that were not injected with ERFP (Figures
3A, 3D, and 3G). In contrast, the majority of DCs ex-under inflammatory conditions (Geissmann et al., 2002;
Randolph, 2002). pressed low levels of pE:I-Ab complexes 4 hr after
ERFP injection. Some of these cells did not containDCs from the draining lymph nodes were enriched by
anti-CD11c magnetic bead selection to facilitate identifi- intact ERFP protein whereas others contained low
amounts (Figures 3B and 3E). The DCs that displayedcation of the relevant subsets. The selected cells were
analyzed by four-color flow cytometry after staining with pE:I-Ab complexes accounted for virtually all of the DCs
that expressed high levels of MHC II (Figures 3E andantibodies specific for B220, I-Ab, and other markers.
B220 cells, which consisted of contaminating B cells 3H). The high levels of MHC II expressed by these cells
Immunity
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Figure 2. Detection of pE:I-Ab Complexes
(A) Popliteal lymph node sections from C57BL/6 mice at different times after subcutaneous injection of 50 g of ERFP in the footpad were
processed and stained with the Y-Ae and anti-B220 antibodies and analyzed by confocal microscopy. Each pair of upper and lower images
depicts the location of ERFP (red, upper rows) or pE:I-Ab complexes (green, lower rows) in the same lymph node section, with B cell-rich
follicles shown in blue. The optical thickness of each image is 9 m. Scale bar, 250 m.
(B and C) Representative flow cytometric analyses of CD11c and ERFP (B) or CD11c and Y-Ae staining (C) of cervical lymph node cells at
the indicated times after subcutaneous injection of 50 g of ERFP in the ear. The percentages of cells in each quadrant are shown.
identified them as tissue-derived Langerhans cells and 3I). Phenotypically, the cells that contained high levels
of ERFP and appeared at 24 hr represented a relativelydermal DCs (Salomon et al., 1998; Ruedl et al., 2000;
Henri et al., 2001). Indeed, the phenotype of the MHC homogeneous population of cells that were CD11b
(Figure 3O, red), CD205int (Figure 3Q, red), indicating thatIIhigh cells was consistent with a mixture of CD8intermediate,
CD11b, CD205high Langerhans cells and CD8low, they were dermal DCs.
Together, these results indicated that at early timesCD11b, CD205int dermal DCs (Figures 3L, 3N, and 3P).
In contrast, the blood-derived MHC IIlow myeloid (CD8, after ERFP injection, the majority of cells displaying
pE:I-Ab complexes were MHC IIhigh Langerhans and der-CD11b) and lymphoid (CD8, CD11b) DCs generated
few detectable pE:I-Ab complexes (Figures 3L and 3N). mal DCs containing low or intermediate levels of ERFP.
At later time points, an additional population of dermalThus, the majority of tissue-derived DCs made pE:I-Ab
complexes at 4 hr, whereas blood-derived DCs did not. DCs bearing high amounts of ERFP and expressing
higher levels of pE:I-Ab complexes appeared in theTwenty-four hours after ERFP injection, the majority
of DCs did not contain intact ERFP (Figures 3C and draining lymph node.
3F), consistent with degradation by antigen processing,
and had similar levels of pE:I-Ab complexes as those Pertussis Toxin Blocks the Appearance of Later
Antigen-Bearing Dendritic Cellsseen at 4 hr (Figures 3C and 3I). In addition, a small
population appeared that contained very high levels of Because the majority of cells displaying pE:I-Ab com-
plexes at both 4 and 24 hr after ERFP injection wereboth ERFP and pE:I-Ab complexes (Figure 3C, red
cells, rectangular gate). This population probably ac- skin-derived DCs, it was possible that these cells ac-
quired ERFP at the injection site and then migratedcounted for the ERFP-containing cells seen in lymph
node sections at later times (Figure 2A). As was ob- into the lymph node. Alternatively, these cells could have
been in the lymph node at the time of injection andserved at 4 hr, the DCs that displayed pE:I-Ab com-
plexes, including the ERFPhigh cells, accounted for virtu- acquired ERFP there. These possibilities were tested
by injecting ERFP subcutaneously with pertussis toxin,ally all of the DCs that expressed high levels of MHC
IIhigh (Figures 3F and 3I), while the MHC IIlow cells were a Gi protein inhibitor that blocks chemokine receptor
signaling and has been shown to prevent leukocyte traf-almost entirely negative for pE:I-Ab complexes (Figure
In Vivo Visualization of Antigen Presentation
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Figure 4. Migration of Dendritic Cells from Skin to Lymph Node Is
Blocked by Pertussis Toxin
Mice were given subcutaneous ear injections of 50 g of ERFP
alone or with pertussis toxin. Lymph node cells were enriched for
cells displaying pE:I-Ab complexes using magnetic bead selection.
pE:I-Ab complexes (Y-Ae staining) and red fluorescence were mea-
sured on selected cells at 0, 3, and 24 hr after antigen injection.
Numbers represent percentages of cells in each quadrant.
ficking (Yang et al., 1999; Sato et al., 2001) and DC
migration from skin painted with a contact sensitizing
chemical (A.A.I., unpublished data). As shown in Figure
4, an equivalent number of skin-derived DCs containing
similar amounts of ERFP and pE:I-Ab complexes were
present in the draining lymph nodes of mice given
ERFP 3 hr earlier with or without pertussis toxin. The
failure of pertussis toxin to block the uptake of ERFP
or the production of pE:I-Ab complexes at 3 hr sug-
gested that these skin-derived DCs acquired ERFP in
the lymph node.
In contrast, injection of ERFP and pertussis toxin
resulted in a 20-fold reduction in the number of dermal
DCs displaying high levels of pE:I-Ab complexes that
normally appeared in the lymph node 24 hr after injection
(Figure 4). The ability of pertussis toxin to block the
appearance of these cells in the lymph nodes indicated
(D–S) I-Ab (D–F) Red fluorescence, (G–I) Y-Ae staining, (J and K)
Figure 3. Identification of Dendritic Cells Displaying pE:I-Ab Com- CD11c, (L and M) CD8, (N and O) CD11b, (P and Q) CD205, or (R
plexes and S) CD3 expression on the same populations of lymph node
(A–C) pE:I-Ab display (Y-Ae staining) and red fluorescence on cells shown in (A–C). The large red dots on the 24 hr dot plot shown
CD11c magnetic bead-selected DCs from cervical lymph nodes, 0, in (C) each represent a cell with the highest levels of ERFP and
4, or 24 hr after subcutaneous injection of 50 g of ERFP in the pE:I-Ab complexes. The position of these cells is shown on the
ear. Cells shown are B220. other 24 hr dot plots.
Immunity
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in the lymph node because these events occurred before
DCs arrived from the injection site.
Consequences of Antigen Presentation
by Resident and Migrant APCs
Since dendritic cells that migrated from the injection
site arrived in the lymph node after the initial activation
of naive T cells (Figure 5), a role for these DC was sought
in later aspects of T cell activation. This was done by
preventing the migration of DCs from the injection site
to the draining lymph node. Pertussis toxin could not
be used for this purpose because it has direct effects
on T cell activation (Stewart et al., 1989). Therefore,
DC migration was prevented by physically removing the
tissue containing the injected antigen (Macher and
Chase, 1969; Balfour et al., 1974). ERFP was injected
into the tip of both ears on individual mice, and 5 hr
Figure 5. Kinetics of pE:I-Ab Complex Display and Early T Cell
later the injection site was surgically removed from oneActivation Events
ear, and a site not containing the antigen from the otherCD4 T cells from TEa mice were transferred into syngeneic recipi-
as a control for effects of the surgery. The activation ofents, which were then given a subcutaneous injection of 50 g
TEa cells was then compared in the cervical lymph nodeof ERFP in the ear. CD69 expression (closed squares) and IL-2
production (open squares) by the TEa T cells and the percentage draining the test or control ear. To ensure that the entire
of CD11c DCs displaying low (open circles) or high (closed circles) injection site could be removed, a smaller amount of
amounts of pE:I-Ab complexes were measured at the indicated ERFP (8g) was injected in a smaller volume (2l) than
times. in earlier experiments. As shown in Figure 6A, removal of
the injection site at 5 hr greatly reduced the appearance
of DCs containing high amounts of ERFP and pE:I-Abthat they acquired ERFP at the injection site. An addi-
complexes at 24 hr (DCs migrating from the injectiontional population of cells expressing low levels of
site), without affecting DCs that acquired low amountspE:I-Ab complexes were observed in the lymph nodes
of ERFP and displayed a low number of pE:I-Ab com-from mice given pertussis toxin. Although these cells
plexes (lymph node-resident skin-derived DCs).expressed intermediate levels of CD11c, they also ex-
The site removal protocol was then used to measurepressed B220 (data not shown) and therefore were not
effects on T cell activation. Following CD69 inductionLangerhans cells or dermal DCs, but instead were phe-
and IL-2 production, antigen-stimulated CD4 T cells ex-notypically similar to plasmacytoid DCs (Nakano et al.,
press the  chain of the IL-2 receptor (CD25), proliferate,
2001). These cells represented only a small percentage
accumulate in the draining lymph node, and differentiate
of lymph node cells under normal circumstances, but
into cells capable of causing a delayed-type hypersensi-
exposure to pertussis toxin may have prevented their tivity (DTH) reaction (Jenkins et al., 2001). TEa T cells in
exit and resulted in the accumulation of these cells. the lymph nodes draining an ear with an intact ERFP
injection site followed this pattern. CD25 was induced
Kinetics of pE:I-Ab Complex Formation and on the majority of cells 1 day after injection, retained on
Activation of pE:I-Ab-Specific CD4 T Cells some of the cells on day 2, and lost by day 3 (Figure
The potential relevance of pE:I-Ab complex displayed 6C). The TEa T cells then proliferated (Figure 6B), accu-
by resident and migrating APCs was assessed by mea- mulated, and declined (Figure 6D). In contrast, TEa
suring the activation kinetics of naive pE:I-Ab-specific T cells in the lymph nodes draining an ear from which
CD4 T cells. This was done by monitoring TEa T cells the ERFP injection site was removed showed slightly
after transfer into C57BL/6 recipients because the fre- less induction of CD25 on day 1 and did not maintain
quency of naive CD4 T cells specific for any given pep- expression on day 2 (Figure 6C), even though the T cells
tide:MHC II complex is below the limit of detection of proliferated (Figure 6B) and accumulated to slightly
flow cytometry (Jenkins et al., 2001). higher levels (Figure 6D) than TEa T cells in the lymph
As shown in Figure 5, the percentage of lymph node- node draining an intact ERFP injection site. Ten days
resident skin-derived cells that displayed low levels of after an injection of ERFP, mice with an intact injection
pE:I-Ab complexes after ERFP injection reached a site mounted a DTH reaction when challenged in the
peak at 3 hr and remained at this level for 24 hr, whereas other ear with ERFP, while mice from which the injec-
DCs from the injection site displaying high levels of tion site was removed showed no more ear swelling than
pE:I-Ab complexes only appeared after 18 hr. Expres- unimmunized mice (Figure 6E). Therefore, the antigen
sion of the activation molecule CD69 on naive TEa cells injection site was important for sustained expression of
occurred shortly after the appearance of pE:I-Ab com- the IL-2 receptor and the generation of a DTH response,
plexes on lymph node-resident skin-derived DCs. In ad- but not clonal expansion.
dition, the TEa cells began to produce IL-2 at 6 hr and
achieved maximal production at 14 hr. Therefore, induc- Discussion
tion of CD69 expression and initial IL-2 production by
naive TEa cells must have been stimulated by pE:I-Ab The results show that the CD4 T cell response to a
subcutaneously injected soluble antigen is initiated bycomplexes displayed by DCs that acquired ERFP when
In Vivo Visualization of Antigen Presentation
53
Figure 6. Effect of Removing the Antigen In-
jection Site on Dendritic Cell Migration and T
Cell Activation
(A) pE:I-Ab complex display and ERFP ac-
quisition on cervical lymph node cells that
did not bind to Y-Ae from mice that did not
receive ERFP (left), or Y-Ae-bead-enriched
cells from the cervical lymph nodes of mice
that were injected 24 hr earlier with 8 g of
ERFP and did (right) or did not (middle) have
the injection site removed 5 hr after injection.
(B) CFSE dye dilution by transferred TEa
T cells from the cervical lymph nodes of mice
that did not receive ERFP (thin line), or mice
that were injected with ERFP and had an
intact injection site (thick line) or had the in-
jection site removed (dashed line) were mea-
sured at the indicated times after ERFP in-
jection.
(C and D) (C) CD25 expression or (D) number
of TEa T cells in the cervical lymph nodes at
the indicated times after ERFP injection in
mice that had an intact injection site (closed
circles) or had the injection site removed at
5 hr (open squares).
(E) Ear swelling 24 hr after injection of ERFP
in mice that were not previously injected with
ERFP, or were injected with ERFP and had
an intact injection site or had the injection
site removed at 5 hr. Ear swelling was mea-
sured in units of 104 inches.
skin-derived DCs that acquire antigen while in the lymph and therefore have not lost antigen processing potential
in vivo as do immature DCs following in vitro maturationnodes. This conclusion is based in part on the observa-
tion that pE-I-Ab complexes were produced by DCs in (Mellman and Steinman, 2001).
Earlier work showed that CD8 DCs produced morethe lymph nodes as early as 30 min after antigen injec-
tion, and that the majority of DCs produced pE-I-Ab peptide:MHC II complexes from a subcutaneously in-
jected antigen than CD8 DCs (Manickasingham andcomplexes at 4 hr after antigen injection. Since it takes
DCs at least several hours to migrate from skin to lymph Reis e Sousa, 2000). Our results suggest that the CD8
DCs identified in that study were Langerhans cells be-nodes (Macatonia et al., 1987; Salomon et al., 1998), not
all of the DCs that displayed pE-I-Ab complexes at cause we found that lymphoid DCs, the other CD8 DC
type in the lymph nodes, did not produce peptide:MHC IIearly times could have migrated from the injection site.
Although it is possible that these cells could have been complexes from subcutaneously injected ERFP. Simi-
larly, our finding that very few myeloid DCs producedin transit in the lymph at the time of injection, the large
fraction of the DCs in the lymph node containing ERFP peptide:MHC II complexes from subcutaneously in-
jected ERFP indicates that the CD11b DCs identifiedat 30 min makes this possibility unlikely. In addition, the
early production of pE-I-Ab complexes by DCs in the as APCs for ovalbumin-specific CD4 T cells in other
experiments were probably tissue-derived DCs (Ver-lymph nodes was not affected by manipulations that
prevent cell migration. Therefore, although the conduit maelen et al., 2001; Ingulli et al., 2002). The relatively
poor uptake of ERFP and subsequent low level produc-network constitutes a significant barrier to the diffusion
of soluble antigens (Gretz et al., 2000), it must allow tion of peptide:MHC II complexes by myeloid and
lymphoid DCs in the lymph nodes could be a result ofthe leakage of some antigen that can be picked up by
resident DCs. Since skin-derived DCs are positioned the less efficient endocytosis of lymph-borne antigens,
as suggested by Ruedl et al. (2001). Indeed, the locationnear the conduits (A.A.I., unpublished data), they may
have an advantage at taking up antigen that leaks out of of lymphoid DCs in the central T cell area away from
the conduits (Ingulli et al., 2002) may limit their accessthe conduits. Our finding that skin-derived DCs produce
peptide:MHC II complexes from lymph-borne antigen to lymph-borne antigen, in contrast to DCs in the spleen
which have access to all the antigen that enters from thewhile in the lymph node supports other work (Inaba et al.,
1998; Manickasingham and Reis e Sousa, 2000; Ruedl et blood. Alternatively, lymphoid DCs may be dedicated to
the production of peptide:MHC I complexes (den Haanal., 2001; Randolph, 2002) indicating that postmigration
DCs residing in the lymph node may not be fully mature et al., 2000; Pooley et al., 2001).
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It was initially surprising to find that epidermal Langer- in mice containing an intact antigen injection site. This
hans cells did not contribute to the population of DCs observation may be explained by the fact that IL-2 is not
that migrated from the injection site and displayed high absolutely required for the proliferation of naive T cells in
levels pE:I-Ab complexes. This finding may simply re- vivo (Kneitz et al., 1995; Khoruts et al., 1998) but is
flect the fact that subcutaneous injection results in the required for the subsequent elimination of activated
deposition of antigen in the dermis of the ear (A.A.I., T cells (Refaeli et al., 1998).
unpublished data), which may give dermal DCs an anti- The requirement for an intact injection site after 5 hr
gen uptake advantage over Langerhans cells. In addi- implies that the generation of the DTH reaction depends
tion, Kamath et al. (2002) have recently shown that der- on APCs or antigen from the site after this time. The
mal DCs appear in the lymph node as early as 24 hr second possibility is unlikely because most of the solu-
after skin painting, whereas Langerhans cells require ble antigen passed through the draining lymph node
3–4 days to migrate from the tissue. This timing of dermal before 5 hr, and lymph node-resident DCs did not con-
DC migration agrees with our observations and likely is tinue to accumulate antigen or peptide:MHC II com-
a factor in explaining the lack of ERFP Langerhans plexes after 5 hr. Alternatively, since activated T cells
cell migrants at 24 hr. migrate to nonlymphoid sites of antigen deposition
Dermal DCs that acquired antigen at the injection site (Reinhardt et al., 2003), it is also possible that the genera-
and migrated to the lymph node contained significantly tion of a DTH response depends on antigen presentation
larger amounts of ERFP and had higher levels of pep- to effector CD4 T cells in the injection site itself. However,
tide:MHC II complexes than the DCs that acquired anti- since removal of the injection site prevented the appear-
gen while in the lymph node. This may be because these ance in the lymph nodes of cells displaying the highest
DCs were exposed to a higher concentration of antigen levels of peptide:MHC II complexes, we favor the idea that
at the injection site than the DCs in the lymph node, presentation by these DCs is required to generate the
which had access only to antigen that leaked out of the effector CD4 T cells that eventually cause DTH.
conduits. It may also reflect the fact that tissue DCs
are relatively immature and are thus capable of storing Experimental Procedures
unprocessed antigen unless confronted with an inflam-
Generation of ERFP Fusion Proteinmatory stimulus (Inaba et al., 2000; Turley et al., 2000).
Two DNA oligomers encoding the sense and antisense sequencesThe DCs that acquired antigen in the tissue may have
of the I-E chain (amino acids 46–74) from the I-Ed allele were synthe-maintained a large store of unprocessed ERFP be-
sized (Research Genetics, Huntsville, AL) and annealed. The double-
cause they migrated under relatively noninflammatory stranded fragment was inserted upstream of the DsRed sequence
conditions. The fact that the ERFP contained trivial in the pDsRed1 plasmid (BD Biosciences Clontech, Palo Alto, CA).
amounts of endotoxin is consistent with this possibility. A fragment containing the E and DsRed sequences was amplified
by PCR and inserted into either the pTYB11 expression vector (NewThe finding that peptide:MHC II presentation by DCs
England Biolabs, Beverly, MA) or the pTrcHis2-TOPO plasmid (In-that acquired antigen while in the lymph nodes was
vitrogen, Carlsbad, CA). Protein production was induced with 1 mMsufficient to drive many aspects of T cell activation dem-
IPTG overnight, and the ERFP fusion protein was purified fromonstrates that resident DCs can initiate the T cell re-
the bacterial lysate using either a chitin-bead affinity column (New
sponse to soluble antigen. This could be relevant to England Biolabs) or a Ni2-resin His-Bind column (Novagen). Endo-
T cell responses specific for microbial debris, secreted toxin was removed from ERFP protein preparations as previously
microbial products, and subunit vaccines. In contrast, described (Aida and Pabst, 1990). Levels of residual endotoxin were
determined to be approximately 0.005 endotoxin units (EU)/g ofthe T cell response to particulate antigens is likely to
ERFP protein using the Limulus amebocyte lysate test (Associatesbe independent of antigen presentation by lymph node-
of Cape Cod Incorporated, Falmouth, MA). This level of residualresident DCs because such antigens cannot access the
endotoxin is roughly equivalent to 4 pg of endotoxin/g of ERFP.conduits. Indeed, it is well established that full T cell
activation results from subcutaneous injection of anti-
Animalsgen-pulsed DCs, a case in which DC migration to the
TEa transgenic mice expressing the Thy1.1 allele were produced
lymph node is probably the only option for antigen pre- by backcrossing the original TEa transgenic mice (Grubin et al.,
sentation. Even for soluble antigen, it follows that some 1997) two times to C57BL.PL-Thy1a mice (purchased from Jackson
low dose would exist at which antigen presentation Laboratory, Bar Harbor, ME). All C57BL/6 mice were purchased from
Jackson Laboratory and were housed under specific pathogen-freewould depend only on the migrating DC because they
conditions. Six- to eight-week-old, sex-matched mice were usedproduce much higher amounts of peptide:MHC complex
for all experiments. Mice were cared for in accordance with thethan resident DCs. However, we were unable to identify
University of Minnesota and NIH guidelines.such a dose of ERFP, which would have been expected
to cause T cell activation at 24 but not 6 hr after injection.
T Cell Adoptive Transfer
Even though the resident DCs were responsible for TEa T cells were identified in lymph node and spleen cell suspen-
the initial T cell activation, the DCs that acquired antigen sions by staining with PE-Cy5-labeled anti-CD4, phycoerythrin (PE)-
at the injection site and migrated to the lymph node were labeled anti-V6, and FITC-labeled anti-V2 antibodies (BD Phar-
needed to sustain the expression of the IL-2 receptor on mingen). T cells were labeled with 5- and 6-carboxy-fluorescein
diacetate succinimidyl ester (CFSE) as previously described (Lyonsthe T cells. Because IL-2 is an autocrine growth factor
and Parish, 1994; Merica et al., 2000), and 2.5  106 labeled cellsfor T cells, it might be predicted that the more transient
were injected intravenously into each C57BL/6 mouse. At variousexpression of the IL-2 receptor by T cells in mice from
times after injection of ERFP, single-cell suspensions from draining
which the antigen injection site was removed would cervical lymph nodes of recipient mice were stained with biotin-
result in less clonal expansion. However, we found that labeled anti-Thy1.1 (BD Pharmingen), PE-Cy5-labeled anti-CD4, and
TEa T cells accumulated to slightly higher levels in the PE-labeled anti-CD25, or PE-labeled anti-CD69 (BD Pharmingen) to
detect the transferred TEa T cells. The number of TEa T cells in alymph nodes under these conditions than did TEa cells
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lymph node was calculated by multiplying the percentage of Thy received the same amount of ERFP, but without prior sensitization.
Swelling was measured with a spring-loaded caliper prior to antigen1.1, CD4 cells by the number of viable cells as determined by
trypan blue dye exclusion. Ex vivo detection of intracellular IL-2 challenge and again 24 hr after challenge. DTH was assayed by the
change in ear thickness of the site of antigen challenge comparedproduced in vivo by TEa cells was performed as previously de-
scribed (Khoruts et al., 1998). with the thickness of the same site prior to challenge.
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